3-Substituted Propionic Acids as AlphaV Integrin Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for fibrotic conditions and cancer associated with αV integrins lack effective αV integrin antagonists, leading to unmet medical needs in diseases such as idiopathic pulmonary fibrosis, liver and kidney fibrosis, and systemic sclerosis.
Innovation Solution
Development of substituted 3-azolopropionic acid compounds that act as αV integrin antagonists, including specific pharmaceutical compositions and processes for their synthesis, which can be used alone or in combination with other therapeutic agents to treat diseases related to αV integrin dysregulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-integrin-mediated mechanisms are used to treat fibrotic conditions, then existing treatments (pirfenidone, nintedanib) can be applied, but the mechanism of action is not directly targeting αV integrins, limiting therapeutic precision
Solution Approach 1:
The patent segments the integrin family targeting by developing compounds specifically against αV integrins (αVβ1, αVβ3, αVβ5, αVβ6, αVβ8) rather than using non-specific integrin inhibitors. This segmentation allows precise targeting of the αV subfamily which is critical for TGF-β activation, thereby improving therapeutic reliability while maintaining ease of manufacture through defined structural requirements (Formula I compounds with specific R1-R12 substituents).
Solution Approach 2:
The invention applies local quality by creating integrin antagonists with specific molecular structures (Formula I) that are tailored to bind selectively to αV integrins. The compounds feature specific substituents at defined positions (R1-R12) that confer selectivity for αV integrins over other integrin subtypes, enabling localized therapeutic action at the αV integrin receptor while maintaining overall drug efficacy.
2Measurement precision
If αV integrin antagonists are developed with high specificity, then therapeutic precision is improved, but compound structure and synthesis complexity increase
Solution Approach 1:
The patent applies universality by establishing a general Formula I structural framework that can generate multiple αV integrin antagonists through variation of substituents (R1-R12). This single formulaic approach provides multi-functionality, allowing synthesis of various compounds with different properties while maintaining αV integrin specificity. The framework covers multiple embodiments (Ia, Ib, Ic, Id, Ie, If) that can be systematically explored without requiring entirely new design approaches for each compound.
Solution Approach 2:
The invention utilizes parameter changes by systematically varying substituent groups at specific positions (R1-R12) within the Formula I framework to optimize compound properties. By changing parameters such as aromatic vs. aliphatic groups, substituent sizes, and chemical functional groups at defined positions, the patent generates a series of compounds with tailored characteristics while maintaining the core αV integrin binding capability, thus achieving specificity without excessive structural complexity.
3Adaptability or versatility
If multiple αV integrin subtypes are targeted, then therapeutic coverage is improved, but selectivity and potential off-target effects become more challenging to manage
Solution Approach 1:
The patent applies dynamics by acknowledging that different αV integrin subtypes (αVβ1, αVβ3, αVβ5, αVβ6, αVβ8) are expressed in different tissues and disease states. The Formula I compound framework provides dynamic adaptability, allowing selection of specific compounds tailored to target particular integrin subtypes based on the disease indication. This dynamic approach enables versatile coverage across multiple subtypes while maintaining safety by selecting appropriate compounds for specific therapeutic contexts rather than using a single pan-integrin agent.
Data Source
AI summary
The present invention provides compounds of Formula (I):or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αV-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αv-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.